An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The primary objective is to study changes in disease related biomarkers in patients with
progressive SSc during treatment with ABR-215757.
The secondary objectives are to assess the safety and tolerability of ABR-215757,to assess
disease activity and quality of life (QoL)during treatment with ABR-215757 and to assess the
plasma levels of ABR-215757 during the study.